Inhaled Allergen Challenge Methodology: Assessment of a Vibrating Mesh Nebulizer for Allergen Administration

Launched by UNIVERSITY OF SASKATCHEWAN · Apr 5, 2018

Keywords

ClinConnect Summary

This will be a multi-center, randomized, cross-over study utilizing the expertise of three Canadian academic centers (University of Saskatchewan, McMaster University, Laval University) that have been performing allergen inhalation challenges and other bronchoprovocation studies for more than forty years.

Each participant will be required to attend the research lab on five occasions (Visits 1-5). At Visit 1, study staff will provide an overview of the study purpose and procedure and answer any questions the participant may have. The individual will then provide consent if they wish to parti...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • baseline FEV1 greater than or equal to 70%
• • positive response to inhaled methacholine (i.e. PD20 less than 400mcg)
• • evidence of atopy (i.e. positive skin prick test to an allergen that can be used for the inhalation challenge
• • absence of respiratory infection for at least 4 weeks
• • absence of allergen exposure (or other trigger of upper or lower respiratory symptoms) for at least 4 weeks
• • current nonsmoker (ex-smoker allowed; case by case basis; investigator discretion)
• • require only infrequent short-acting beta2 agonist (i.e. salbutamol or terbutaline) to treat/control asthma (i.e. no inhaled corticosteroid or combination therapies, no intranasal corticosteroid; anti-histamines etc.)
• • general good health with no other medical condition, medication use or lifestyle activities that would influence the outcome of the allergen challenge
• Exclusion Criteria:
• • pregnant or lactating